Data Extraction Errors in Meta-analyses That Use Standardized Mean Differences

Gøtzsche, Peter C; Hróbjartsson, Asbjørn; Maric, Katja L; Tendal, Britta

doi:10.1001/jama.298.4.430

Cited by 172 publications

(178 citation statements)

References 58 publications

Supporting

Mentioning

168

Contrasting

Unclassified

Order By: Relevance

“…In addition to broadening inclusion criteria, original meta-analyses should go through a much more rigorous review than they do now, particularly with respect to the accuracy of the analyses. Like any other type of quantitative study, calculation and reporting errors can and do happen in meta-analysis (e.g., Gøtzsche, Hróbjartsson, Marić, & Tendal, 2007). Since others will be using the same metaanalytic dataset to test their hypotheses via meta-reanalysis, it will be crucial to ensure original calculations and reports are accurate; the impact of calculation and reporting errors will be exponentially compounded by subsequent meta-reanalysis.…”

Section: Changes To Meta-analytic Methodsmentioning

confidence: 99%

Exploring Small, Confirming Big: An alternative system to The New Statistics for advancing cumulative and replicable psychological research

Sakaluk

2016

Journal of Experimental Social Psychology

View full text Add to dashboard Cite

Section: Changes To Meta-analytic Methodsmentioning

confidence: 99%

Exploring Small, Confirming Big: An alternative system to The New Statistics for advancing cumulative and replicable psychological research

Sakaluk

2016

Journal of Experimental Social Psychology

View full text Add to dashboard Cite

“…If necessary, disagreements were resolved through a third-party arbitrator (J.A.K.). Additionally, to minimize the risk of data abstraction errors, the corresponding authors of the reviewed studies were contacted for clarification of study procedures (27).…”

Section: Data Abstraction and Risk Of Bias Assessmentmentioning

confidence: 99%

Interventions to Reduce Rehospitalizations after Chronic Obstructive Pulmonary Disease Exacerbations. A Systematic Review

Prieto-Centurion¹,

Markos

Ramey³

et al. 2014

Annals ATS

View full text Add to dashboard Cite

Rationale: Approximately 20% of patients hospitalized for COPD exacerbations in the United States will be readmitted within 30 days. The Centers for Medicare and Medicaid Services has recently proposed to revise the Hospital Readmissions Reduction Program to financially penalize hospitals with high all-cause 30-day rehospitalization rates after a hospitalization for COPD exacerbation on or after October 1, 2014.Objectives: To report the results of a systematic review of randomized clinical trials evaluating interventions to reduce the rehospitalizations after COPD exacerbations.Methods: Multiple electronic databases were systematically searched to identify relevant studies published between January 1966 and June 2013. Titles, abstracts, and, subsequently, full-text articles were assessed for eligibility. Each study was appraised using predefined criteria.Measurements and Main Results: Among 913 titles and abstracts screened, 5 studies (1,393 participants) met eligibility criteria. All studies had a primary outcome of rehospitalization at 6 or 12 months. No study examined 30-day rehospitalization as the primary outcome. Each study tested a different set of interventions. Two studies (one conducted in Canada and one conducted in Spain and Belgium) showed a decrease in all-cause rehospitalization over 12 months in the intervention group versus comparator group (mean number of hospitalizations per patient, 1.0 vs. 1.8; P = 0.01; percent hospitalized, 45 vs. 67%; P = 0.028; respectively). The only study conducted in the United States found a greater than twofold higher risk of mortality in the intervention group (17 vs. 7%, P = 0.003) but no significant difference in rehospitalizations. It was unclear which set of interventions was effective or harmful. Conclusions:The evidence base is inadequate to recommend specific interventions to reduce rehospitalizations in this population and does not justify penalizing hospitals for high 30-day rehospitalization rates after COPD exacerbations.

show abstract

“…Two reviewers (K.I. and T. S.) independently conducted each analysis to minimize data management errors (13).…”

Section: Methodsmentioning

confidence: 99%

Effect of Neutrophil Elastase Inhibitor (Sivelestat Sodium) in the Treatment of Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrome (ARDS): A Systematic Review and Meta-Analysis

et al. 2010

View full text Add to dashboard Cite

Introduction Sivelestat is neutrophil elastase inhibitor, which is widely used in Japan for the treatment of acute lung injury. However, the clinical efficacy of the medication has not been convincingly demonstrated. Methods We conducted a systematic review and meta-analysis of randomized controlled trials on sivelestat for the treatment of acute lung injury and acute respiratory distress syndrome. Studies were identified using MEDLINE, EMBASE, Cochrane library, conference proceedings, and references of included studies. Authors were contacted if necessary. ICHUSHI, the Japanese database for medical literature and conference proceedings was also used for the search, since many studies on sivelestat were published in Japanese language and not registered in major databases such as MEDLINE. The primary outcome was mortality within 28-30 days after randomization. Relative risks were pooled with the random effect model. Results 8 trials were included in the analysis. There was no difference in mortality within 28-30 days after randomization (relative risk 0.95, 95% confidence interval 0.72 to 1.26). Subgroup analysis conducted only on studies conducted in Japan showed the same result (0.59, 0.28 to 1.28). There was no difference in mechanical ventilation days (standardized mean difference -0.43, -1.12 to 0.27), but sivelestat was associated with a better short term PaO2/FiO2 ratio (0.30, 0.05 to 0.56). Heterogeneity was not significant for the main analysis and funnel plot did not suggest publication bias. Conclusion Sivelestat was not associated with decreased mortality, even when including studies published in Japanese language.

show abstract

Data Extraction Errors in Meta-analyses That Use Standardized Mean Differences

Cited by 172 publications

References 58 publications

Exploring Small, Confirming Big: An alternative system to The New Statistics for advancing cumulative and replicable psychological research

Exploring Small, Confirming Big: An alternative system to The New Statistics for advancing cumulative and replicable psychological research

Interventions to Reduce Rehospitalizations after Chronic Obstructive Pulmonary Disease Exacerbations. A Systematic Review

Effect of Neutrophil Elastase Inhibitor (Sivelestat Sodium) in the Treatment of Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrome (ARDS): A Systematic Review and Meta-Analysis

Contact Info

Product

Resources

About